Aerie Pharmaceuticals
AERI
AERI was delisted on the 18th of November, 2022.
158 hedge funds and large institutions have $830M invested in Aerie Pharmaceuticals in 2021 Q1 according to their latest regulatory filings, with 28 funds opening new positions, 46 increasing their positions, 61 reducing their positions, and 19 closing their positions.
47% more first-time investments, than exits
New positions opened: 28 | Existing positions closed: 19
38% more capital invested
Capital invested by funds: $601M → $830M (+$229M)
5% more funds holding
Funds holding: 150 → 158 (+8)
25% less repeat investments, than reductions
Existing positions increased: 46 | Existing positions reduced: 61
25% less call options, than puts
Call options by funds: $3.8M | Put options by funds: $5.06M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WP
Woodline Partners
San Francisco,
California
|
+$37.3M |
| 2 |
GIM
Granahan Investment Management
Waltham,
Massachusetts
|
+$14.3M |
| 3 |
Principal Financial Group
Des Moines,
Iowa
|
+$9.14M |
| 4 |
RCMNY
Rubric Capital Management (New York)
New York
|
+$8.3M |
| 5 |
ACM
Atika Capital Management
New York
|
+$8.29M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DM
Deerfield Management
New York
|
-$11.5M |
| 2 |
VOYA Investment Management
Atlanta,
Georgia
|
-$7.87M |
| 3 |
First Manhattan
New York
|
-$6.14M |
| 4 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
-$5.91M |
| 5 |
Bank of America
Charlotte,
North Carolina
|
-$5.87M |
AERI Hedge Fund Activity: Q1 2021 in Review
158 of the 5,696 institutional investors tracked by Wall St. Rank reported a position in Aerie Pharmaceuticals (AERI) for Q1 2021, worth a combined $830M — up 38% from $601M a quarter earlier.
Buyers outnumbered sellers: 28 funds opened new AERI positions and 19 closed out — a net gain of 9 holders — while 46 added to existing stakes and 61 trimmed.
The largest buyer was Woodline Partners, opening a new position worth an estimated $37.3M. The largest seller was Deerfield Management, cutting an estimated $11.5M.
- 158 institutional investors held Aerie Pharmaceuticals (AERI) as of Q1 2021, up from 150 in Q4 2020.
- Funds reported $830M of Aerie Pharmaceuticals stock for Q1 2021, up 38% quarter-over-quarter.
- 28 funds opened new Aerie Pharmaceuticals positions in Q1 2021 and 19 closed out, a net change of +9 holders.
- The largest Aerie Pharmaceuticals buyer in Q1 2021 was Woodline Partners, an estimated $37.3M added.
- The largest Aerie Pharmaceuticals seller in Q1 2021 was Deerfield Management, an estimated $11.5M sold.
Based on aggregated 13F filings for Q1 2021.